News

San Antonio biotech acquires U.K. wound-care company

Acelity LP President and CEO Andrew Eckert says the company's acquisition of England's Crawford Healthcare ...

Kiromic founder says Houston biotech’s move to SA nearly a done deal

Houston-based immunotherapy company Kiromic is expected this month to approve moving its headquarters ...

Events

4th Annual SURF 2018

What: San Antonio Military Health System and Universities ResearchForum When: Thursday, June ...

SwRI 2018 International Human Performance Summit

June 30-July 1, 2018 The Summit will be hosted by Southwest Research Institute as part of its ongoing ...
News
San Antonio’s Mission Pharmacal rolls out two new products
November 19, 2015

By Peggy O'Hare on November 19, 2015 at 3:27 PM

San Antonio pharmaceutical company Mission Pharmacal has introduced two new medications for adults suffering from coughs and colds.

The company has nationally launched HycofenixT Oral Solution, a prescription medication that relieves three cough and cold symptoms. The product features the first and only combination of hydrocodone, pseudoephedrine and guaifenesin approved by the U.S. Food and Drug Administration.

Hycofenix relieves coughing, loosens respiratory secretions for a more productive cough and clears nasal congestion.

Mission Pharmacal also launched another new product, FlowtussT Oral Solution, a prescription that relieves coughing and loosens respiratory secretions. The medication is an option for patients who are coughing, but do not need a nasal decongestant. It contains hydrocodone bitartrate and guaifenesin.

Both medications come in a black raspberry flavor and have been approved by the FDA for patients 18 years old and older.

To support customer needs related to Hycofenix and Flowtuss, we have nearly doubled the size of our sales team, said John McLaughlin, sales director of Mission Pharmacal’s primary care division. We are excited that the addition of these products in a new therapeutic class enables us to grow and better serve primary care providers and their patients.

Stay informed. Subscribe to BioMed SA news alerts.